A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

Hyperphosphatemia is associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering medication on vascular calcification and arterial stiffness in CKD remain uncertain. To assess the effects of non-calcium-based phos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2020-11, Vol.31 (11), p.2653-2666
Hauptverfasser:	Toussaint, Nigel D, Pedagogos, Eugenia, Lioufas, Nicole M, Elder, Grahame J, Pascoe, Elaine M, Badve, Sunil V, Valks, Andrea, Block, Geoffrey A, Boudville, Neil, Cameron, James D, Campbell, Katrina L, Chen, Sylvia S M, Faull, Randall J, Holt, Stephen G, Jackson, Dana, Jardine, Meg J, Johnson, David W, Kerr, Peter G, Lau, Kenneth K, Hooi, Lai-Seong, Narayan, Om, Perkovic, Vlado, Polkinghorne, Kevan R, Pollock, Carol A, Reidlinger, Donna, Robison, Laura, Smith, Edward R, Walker, Robert J, Wang, Angela Yee Moon, Hawley, Carmel M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aorta, Abdominal Clinical Research Double-Blind Method Female Fibroblast Growth Factors - blood Glomerular Filtration Rate Humans Hyperphosphatemia - blood Hyperphosphatemia - drug therapy Hyperphosphatemia - etiology Lanthanum - adverse effects Lanthanum - therapeutic use Male Middle Aged Parathyroid Hormone - blood Phosphates - blood Phosphates - urine Pulse Wave Analysis Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - physiopathology Tomography, X-Ray Computed Vascular Calcification - diagnostic imaging
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!